HC Wainwright Comments on Nicox S.A.’s Q1 2024 Earnings (OTCMKTS:NICXF)

Nicox S.A. (OTCMKTS:NICXF) – Stock analysts at HC Wainwright decreased their Q1 2024 EPS estimates for Nicox in a research report issued to clients and investors on Tuesday, April 23rd. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($0.03) per share for the quarter, down from their previous forecast of ($0.02). The consensus estimate for Nicox’s current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Nicox’s Q3 2024 earnings at ($0.07) EPS.

Nicox Stock Performance

Shares of NICXF opened at $0.44 on Thursday. Nicox has a 12 month low of $0.44 and a 12 month high of $0.44. The firm has a fifty day simple moving average of $0.44 and a 200 day simple moving average of $0.52.

About Nicox

Nicox SA operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial.